TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

CHENGDU

OncologyOphthalmologyMetabolic
Generics

CHENGDU is a generic drug manufacturer focused on Oncology, Ophthalmology, Metabolic.

2024
Since
1
Drugs
-
Trials
25
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

TACROLIMUS 2025-10-17
Labeling
TACROLIMUS 2025-10-17
Labeling
TACROLIMUS 2025-10-17
Labeling
TACROLIMUS 2025-10-17
Labeling
TACROLIMUS 2025-09-26
Labeling
TACROLIMUS 2025-09-26
Labeling
TACROLIMUS 2025-09-04
Labeling
TACROLIMUS 2025-05-19
Labeling
TACROLIMUS 2025-05-19
Labeling
TACROLIMUS 2025-05-19
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 53%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 16
Ophthalmology 33%
0 drugs Phase 3: 4 Phase 1: 4
Metabolic 7%
0 drugs Phase 3: 1
Dermatology 3%
0 drugs Phase 2: 1
Infectious Disease 3%
0 drugs Phase 2: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Baxter specialty
Infectious Disease, Oncology, Dermatology, Ophthalmology
Bayer big-pharma
Oncology, Ophthalmology, Dermatology, Metabolic
B BRAUN specialty
Infectious Disease, Ophthalmology, Dermatology, Metabolic
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
KING PHARMS LLC big-pharma
Infectious Disease, Dermatology, Oncology, Metabolic